UroGen Pharma Ltd. (URGN) - Stock Analysis
Last updated: Jan 15, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
UroGen Pharma is trading on optimism ahead of an FDA decision for UGN-102, with the stock showing a steady rebound. A positive approval could drive rapid upside, but legal overhang and cash burn add risk. Near-term technical levels offer clear entry and stop points.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High gross margin ⢠Severe cash burn ⢠Negative equity URGN combines very high gross margins and solid nearâterm liquidity with persistent operating losses, heavy R&D/opex cash burn and negative equity that create significant solvency and valuation risk.
Price Behavior
Key Price Behavior Insights: ⢠Downward trend ⢠Broke support ⢠Strong selling Support Level: $22â$23 Resistance Level: $28.00 URGN has trended lower over the last month from about $23.58 to $19.83, breaking short-term support and showing steep selling pressure that favors caution for near-term momentum.
Sentiment & News
Key News Insights: ⢠Institutional divergence ⢠Jâcode approval ⢠Access-driven revenue UroGen saw contrasting institutional movesâwith Squarepoint increasing its stake while Wildcat fully exitedâwhile securing a permanent Jâcode for ZUSDURIâ˘, boosting patient access and revenue potential.
AI Summary
UroGen's investment case has shifted from a binary clinical gamble to an execution-focused commercialization bet where the company must rapidly convert PEFs to repeat ZUSDURI doses and/or deliver an onâschedule UGNâ103 NDA to materially extend runway; failing to show quarterâoverâquarter ZUSDURI revenue acceleration or secure nonâdilutive funding will likely force dilutive financing and justify deârisking the position. Monitor PEFâtoâdose timelines, Q/Q ZUSDURI sales growth, and cash runway (cash vs. ~$30â$40M quarterly burn) as the specific triggers that will reârate the stock.
Description
UroGen Pharma Ltd. is a biotechnology company developing treatments for urothelial diseases and specialty cancers, using a biocompatible reverse thermal gel platform to modify drug delivery and exposure. Its pipeline includes UGN-102, currently in Phase III for several forms of non-muscle invasive urothelial cancer, and UGN-301 for high-grade disease, alongside a commercial offering based on its hydrogel technology. The company maintains licensing and development agreements with Allergan and Agenus and a research collaboration with MD Anderson, and is based in Princeton, New Jersey (incorporated 2004).
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 21 | Jul 28 | URGN | UroGen Pharma Ltd. | UroGen Pharma is trading on optimism ahead of an FDA decision for UGN-102, with the stock showing a steady rebound. A positive approval could drive rapid upside, but legal overhang and cash burn add risk. Near-term technical levels offer clear entry and stop points. | Closed | +22.3% |